Nancy Whiting Buys Shares of Boundless Bio, Inc. $BOLD
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Nancy Whiting, insider at Boundless Bio, Inc. ($BOLD), bought 32,000 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Boundless Bio, Inc. Stock Down 50.5%
Shares of Boundless Bio, Inc. ($BOLD) traded around $1.40 on Tuesday, down 50.5% for the day.
Boundless Bio, Inc. Earnings
Analysts Set New Price Targets
About Boundless Bio, Inc.
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Get Boundless Bio, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BOLD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.